Literature DB >> 11257355

Conjugates and reverse vaccinology to eliminate bacterial meningitis.

R Rappuoli1.   

Abstract

Bacterial meningitis is caused mainly by Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis. Haemophilus influenzae type b vaccines have been extremely successful in eradicating the disease from those countries where the vaccine has been introduced. The recent licensure of the conjugated pneumococcal vaccine suggests that this pathogen also will be soon controlled. Consequently, if we succeed in developing effective vaccines against meningococcus, this will enable us to eliminate bacterial meningitis. The global elimination of bacterial meningitis is a goal which, if appropriate resources are applied, can be reached within the first fifteen years of the 21st century.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257355     DOI: 10.1016/s0264-410x(00)00552-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines.

Authors:  Mathew A Diggle; Stuart C Clarke
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

2.  Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.

Authors:  Nikunj M Shukla; Tyler C Lewis; Timothy P Day; Cole A Mutz; Rehman Ukani; Chase D Hamilton; Rajalakshmi Balakrishna; Sunil A David
Journal:  Bioorg Med Chem Lett       Date:  2011-04-20       Impact factor: 2.823

3.  Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens.

Authors:  N Ariel; A Zvi; K S Makarova; T Chitlaru; E Elhanany; B Velan; S Cohen; A M Friedlander; A Shafferman
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

4.  Product review on the IMD serogroup B vaccine Bexsero®.

Authors:  Ala-Eddine Deghmane; Muhamed-Kheir Taha
Journal:  Hum Vaccin Immunother       Date:  2022-02-22       Impact factor: 3.452

5.  Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes.

Authors:  Gino J E Baart; Bert Zomer; Alex de Haan; Leo A van der Pol; E Coen Beuvery; Johannes Tramper; Dirk E Martens
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

Review 6.  Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.

Authors:  Huub F J Savelkoul; Valerie A Ferro; Marius M Strioga; Virgil E J C Schijns
Journal:  Vaccines (Basel)       Date:  2015-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.